argenx Valuation Multiples

argenx Overview

About argenx

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Founded

2008

HQ

Employees

2.4K

Website

argenx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5B

EBITDA: $1B

EV

$48B

Valuation Multiples

Multiples.vc

Start free trial

argenx Financials

argenx reported last 12-month revenue of $5B and EBITDA of $1B.

In the same LTM period, argenx generated $4B in gross profit, $1B in EBITDA, and $1B in net income.

argenx P&L

In the most recent fiscal year, argenx reported revenue of $4B and EBITDA of $1B.

argenx expects next 12-month revenue of XXX and NTM EBITDA of XXX

argenx Stock Performance

argenx has current market cap of $52B, and enterprise value of $48B.

argenx's stock price is $838.96.

argenx Valuation Multiples

argenx trades at 10.0x EV/Revenue multiple, and 34.1x EV/EBITDA.

argenx Financial Valuation Multiples

As of April 18, 2026, argenx has market cap of $52B and EV of $48B.

Equity research analysts estimate argenx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

argenx has a P/E ratio of 36.7x.

argenx Margins & Growth Rates

argenx's revenue in the last 12 month grew by 34%.

argenx's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $1.1M for the same period.

argenx's rule of 40 is 79% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

argenx's rule of X is 146% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

argenx Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

argenx M&A Activity

argenx acquired XXX companies to date.

Last acquisition by argenx was on XXXXXXXX, XXXXX. argenx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

argenx Investment Activity

argenx invested in XXX companies to date.

argenx made its latest investment on XXXXXXXX, XXXXX. argenx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).